Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.
暂无分享,去创建一个
K. Sułek | D. Nowis | J. Gołąb | G. Basak | M. Jakóbisiak | J. Bil | K. Bojarczuk | M. Winiarska | A. Dabrowska-Iwanicka | A. Dąbrowska-Iwanicka